EFM
VKTX icon

E Fund Management’s Viking Therapeutics VKTX Stock Holding History

E Fund Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$547K Sell
14,026
-1,830
-12% -$59.1K 0.01% 245
2026
Q1 		$516K Buy
+15,856
New +$510K 0.02% 287
2025
Q2 		$466K Buy
17,580
+406
+2% +$10.7K 0.02% 237
2025
Q1 		$415K Sell
17,174
-2,098
-11% -$66.3K 0.02% 245
2024
Q4 		$776K Buy
19,272
+2,992
+18% +$171K 0.04% 174
2024
Q3 		$1.03M Sell
16,280
-4,100
-20% -$241K 0.05% 141
2024
Q2 		$1.08M Buy
20,380
+14,342
+238% +$940K 0.06% 121
2024
Q1 		$495K Sell
6,038
-16,157
-73% -$719K 0.03% 159
2023
Q4 		$413K Sell
22,195
-6,582
-23% -$86.1K 0.03% 194
2023
Q3 		$319K Buy
28,777
+10,374
+56% +$148K 0.02% 201
2023
Q2 		$298K Sell
18,403
-12,273
-40% -$257K 0.02% 218
2023
Q1 		$511K Buy
+30,676
New +$317K 0.04% 126
2021
Q1 		$92K Buy
+14,481
New +$102K 0.01% 244

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

E Fund Management's VKTX Position: Q2 2026 in Review

E Fund Management reduced its Viking Therapeutics (VKTX) stake by 12% in Q2 2026, selling an estimated $59.1K and leaving 14,026 shares worth $547K. The position accounts for 0.01% of the portfolio, ranked #245.

E Fund Management first reported a position in VKTX in Q1 2021 and has held it in 13 quarters since. The position peaked at $1.08M in Q2 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • E Fund Management held 14,026 shares of Viking Therapeutics worth $547K as of Q2 2026.
  • E Fund Management sold 1,830 Viking Therapeutics shares in Q2 2026, an estimated $59.1K.
  • Viking Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #245 holding.
  • E Fund Management first reported a position in Viking Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • E Fund Management's Viking Therapeutics position peaked at $1.08M in Q2 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.